| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19, 2022 | LQDA Liquidia Corp | Caligan Partners LP58 | Director, 10% Owner, See Remarks | Buy | 221,104 | $5.89 | $1,301,472.56 | +0.7% | +24.6% | +43.6% | |
| May 18, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 9,924 | $35.05 | $347,826.28 | -10.3% | -4.5% | +28.7% | |
| May 18, 2022 | LNTH Lantheus Holdings, Inc. | Niedzwiecki Daniel54 | See Remarks | Sell | 1,380 | $64.54 | $89,062.44 | -1.9% | +32.6% | +52.8% | |
| May 18, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 700 | $302.00 | $211,400.00 | - | +5.5% | +49.2% | |
| May 17, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 19,683 | $302.26 | $5,949,342.97 | - | +4.5% | +46.0% | |
| May 17, 2022 | ESPR Esperion Therapeutics, Inc. | Warren Eric60 | Chief Commercial Officer | Sell | 196 | $5.98 | $1,172.28 | -0.4% | +2.3% | -73.0% | |
| May 17, 2022 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 50,000 | $29.15 | $1,457,475.00 | -17.7% | -10.4% | +4.4% | |
| May 17, 2022 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 130,000 | $8.22 | $1,068,067.00 | -98.9% | +33.3% | -3.2% | |
| May 17, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Zhang Jack Y.45 | CEO &Chief Scientific Officer | Sell | 118,445 | $35.75 | $4,234,897.09 | -1.3% | -9.5% | +19.6% | |
| May 17, 2022 | DVAX Dynavax Technologies Corp | Burgess Justin60 | Principal Accounting Officer | Sell | 6,000 | $10.00 | $60,000.00 | -60.9% | +60.5% | +14.4% | |
| May 17, 2022 | ORGO Organogenesis Holdings Inc. | Gillheeney Gary S.73 | President And CEO | Sell | 314,837 | $6.02 | $1,895,557.68 | -15.5% | -17.7% | -46.3% | |
| May 16, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Zasloff Michael A53 | Director | Sell | 10,291 | $35.61 | $366,499.56 | -17.9% | -8.0% | +21.4% | |
| May 16, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 80,761 | $302.53 | $24,432,992.96 | - | +5.2% | +46.7% | |
| May 16, 2022 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.53 | CFO And Treasurer | Sell | 10,000 | $63.27 | $632,700.00 | -6.9% | +25.1% | +45.7% | |
| May 16, 2022 | ORGO Organogenesis Holdings Inc. | Katz Michael W | 10% Owner | Buy | 10,000 | $6.03 | $60,297.80 | +5.2% | -15.9% | -47.5% | |
| May 16, 2022 | PFE Pfizer Inc | Damico Jennifer B.58 | SVP &Controller | Sell | 4,000 | $50.50 | $202,000.00 | -21.0% | -1.1% | -25.8% | |
| May 13, 2022 | LNTH Lantheus Holdings, Inc. | Blanchfield Paul54 | Chief Commercial Officer | Sell | 2,285 | $60.95 | $139,270.75 | -3.0% | +30.2% | +55.7% | |
| May 13, 2022 | PFE Pfizer Inc | Sahni Payal | Executive Vice President | Sell | 1,408 | $49.84 | $70,174.72 | -7.5% | -2.5% | -24.0% | |
| May 12, 2022 | PFE Pfizer Inc | Lankler Douglas M | Executive Vice President | Sell | 38,273 | $49.41 | $1,891,068.93 | -32.7% | -0.1% | -24.7% | |
| May 12, 2022 | ASRT Assertio Holdings, Inc. | McKee William | Director | Sell | 22,322 | $2.35 | $52,487.95 | -8.9% | +52.1% | +190.9% | |
| May 12, 2022 | ASRT Assertio Holdings, Inc. | Tyree James L51 | Director | Sell | 44,643 | $2.36 | $105,169.98 | -17.5% | +52.1% | +190.9% | |
| May 12, 2022 | PFE Pfizer Inc | Carapezzi William R Jr | Executive Vice President | Sell | 32,908 | $50.00 | $1,645,400.00 | -46.3% | -0.1% | -24.7% | |
| May 11, 2022 | PFE Pfizer Inc | Dolsten Mikael56 | President R&D | Sell | 63,902 | $49.32 | $3,151,547.14 | -2.7% | +2.3% | -22.1% | |
| May 11, 2022 | ANIK Anika Therapeutics, Inc. | Colleran David | EVP, General Counsel, Corp Sec | Buy | 1,500 | $21.37 | $32,055.00 | +17.9% | +6.4% | +19.4% | |
| May 11, 2022 | ELAN Elanco Animal Health Inc | Bilbrey John P49 | Director | Buy | 10,000 | $22.03 | $220,284.00 | +41.3% | -8.1% | -57.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.